Mutation of tryptophan-101 in Clostridium difficile toxin A, a 308-kDa glucosyltransferase, resulted in a 50-fold-reduced cytopathic activity in cell culture experiments. The mutant toxin A was characterized and applied to distinguish between glucosyltransferase-dependent and -independent effects with respect to RhoB up-regulation as a cellular stress response.
Clostridium difficile toxins A and B (TcdA and TcdB, respectively) are the major pathogenicity factors that are causative for antibiotic-associated pseudomembranous colitis (19) . Several reports of the in vivo effects of TcdA in animal models reflect efforts to understand the cellular mechanism leading to clinical symptoms as well as to the release of mediators that are involved in the inflammatory process (2, 13, 15, 18, 20) . The inherent glucosyltransferase
FIG. 1. (A)
In vitro glucosyltransferase activities of wild-type and mutant rTcdA with the substrate RhoA. Enzyme activities were calculated for rTcdA (16.6 mol/mol · min), rTcdA W101A (0.044 mol/mol · min), and rTcdA D285/287N (2.4 ϫ 10 Ϫ3 mol/mol · min) (data are means Ϯ standard deviations [SD] ; n ϭ 4 [for rTcdA D285/287N, n ϭ 3]). (B) The kinetics of cell rounding by 0.1 nM wild-type rTcdA (F) and 5 nM rTcdA W101A (OE) were identical, whereas 0.1 nM rTcdA W101A (E) and rTcdA D285/287N (‚) did not cause rounding of cells within a period of 3 h (data are means Ϯ SD; n ϭ 5). (C) The integrity of Caco-2 cell monolayers was checked by measuring the TER after treatment with the indicated toxins applied to the apical site for 7 h. Only cells treated with 0.15 nM wild-type rTcdA (F) or 7.5 nM rTcdA W101A (OE) showed significant decreases in the TER, whereas cells treated with 0.15 nM rTcdA W101A (E) or 7.5 nM rTcdA D285/287N (‚) were not affected (data are means Ϯ SD; n ϭ 3).
(GT) activity of TcdA/B, which catalyzes monoglucosylation of the small GTPases Rho, Rac, and Cdc42, is well described (11, 12) . However, Rho inactivation is not in accordance with the activation of Rho-dependent proinflammatory signal cascades (14) . To address the issue of GT-independent effects, we used recombinant TcdA (rTcdA) (4, 10) and generated two mutant toxins by site-directed mutagenesis of the expression vector. Two highly conserved motifs were chosen for mutation, namely, tryptophan-101 and the DXD motif at positions 285 to 287 (3, 17) . Analogous mutations of TcdB resulted in reductions of the in vitro GT activity, by factors of 1,000 and 5,000, respectively (5, 6, 16) . The in vitro GT activities of rTcdA (wild type), rTcdA W101A (tryptophan mutant), and rTcdA D285/287N (DXD mutant) were determined from the linear phases of RhoA glucosylation kinetics (Fig. 1A) , as described elsewhere (7) . The GT activities of the W101A and D285/287N mutants were reduced 380-fold and 6,900-fold, respectively, compared to that of wild-type rTcdA. In contrast to the case in the cellfree system, the cytopathic activity of rTcdA W101A on Swiss 3T3 fibroblasts was estimated to be reduced only 50-fold (Fig. 1B) . In addition, the colonic cell line Caco-2 was used to investigate the cytopathic property of mutant toxins with respect to transepithelial electrical resistance (TER). The TER of confluent Caco-2 cell monolayers grown on filter inserts (Falcon; BD, Germany) was determined, starting with an initial value of at least 150 ⍀ · cm 2 ( Fig. 1C) . To check the extent of intracellular glucosylation of GTPases, unmodified GTPases were detected by either sequential 14 C-glucosylation (RhoA/B and Rac1) (12), [
32 P]ADP ribosylation (RhoA/B) (1), or Western blot analysis (with antiRac1, which exclusively recognizes unmodified Rac1) (8) . There was a concentration-dependent decrease in sequential 14 C-glucosylation ( Fig. 2A ) that was obvious in cells incubated with 1.5 nM or higher concentrations of rTcdA W101A. Figure 2B shows the concentration-and timedependent glucosylation of RhoA/B and Rac1 by rTcdA W101A. The amounts of nonglucosylated RhoA/B and Rac1 in 3T3 fibroblasts treated for 2 or 4 h with different concentrations of rTcdA W101A were almost identical in the respective cell lysates (Fig. 2B, left panel) . The glucosylation kinetics of RhoA/B and Rac1 by rTcdA W101A (5 nM) did not differ significantly from those by rTcdA (0.1 nM) (Fig.  2B, right panel) .
To check whether the previously reported up-regulation of the immediate-early gene product RhoB (9) is dependent on the GT activity of TcdA, enzyme activity-deficient rTcdA and rTcdA with reduced enzyme activity were applied. rTcdA (0.1 nM) induced strong synthesis of the RhoB protein in Swiss 3T3 fibroblasts after 4 h (Fig. 3, inset) . Enzyme activity-deficient rTcdA D285/287N had no effect on RhoB up-regulation, even at a concentration of 100 nM, whereas the tryptophan mutant toxin (rTcdA W101A) showed a concentration-dependent effect. Thus, significant RhoB up-regulation was detected only with those concentrations of tryptophan mutant toxin that were sufficient to cause cytopathic effects. The concentrationdependent up-regulation of RhoB in correlation with cell rounding was determined in quadruplicate, and the results are displayed in Fig. 3 .
The N-terminal fragment of TcdA encompasses amino acids 1 to 1065 (⌬rTcdA) and consists of the minimal catalytic domain (amino acids 1 to 542) plus the portion up to the putative transmembrane region. However, ⌬rTcdA lacks the transmembrane and receptor binding domains and is therefore incapable of entering target cells. The specific GT activities of ⌬rTcdA and ⌬rTcdA W101A were 10.3 mol/ mol · min and 0.04 mol/mol · min, respectively ( Fig. 4A and B) and thus did not differ significantly from the GT activities of the corresponding holotoxins. To deliver the N-terminal fragments into intact cells by circumventing the active process of endocytosis, the electroporation technique (3 F, 500 V) was applied (5) . The minimal concentration of ⌬rTcdA that induced an irreversible decrease in the TER over a period of 5 h was determined (Fig. 4C) . A time course of TER measurements for Caco-2 cell monolayers was performed with ⌬rTcdA, ⌬rTcdA W101A, and 50 l Bacillus megaterium protein fraction as a negative control for protein impurities (Fig. 4D) . Mean values after 6 h of treatment for three separate experiments are shown in Fig. 4E . To complete the study of the intracellular effects of ⌬rTcdA and ⌬rTcdA W101A, sequential 14 C-glucosylation of the cell lysates of electroporated monolayers was performed (Fig.  4F, upper panel) . Compared to controls, there was no decrease in sequential 14 C-glucosylation of lysates from cells treated with 1.5 nM ⌬rTcdA W101A, but there was a reduction of about 40% in lysates from cells treated with either 75 nM ⌬rTcdA W101A or 1.5 nM ⌬rTcdA. In accordance with the effects on the TER and sequential 14 C-glucosylation, up-regulation of RhoB was induced only by 1.5 nM ⌬rTcdA and 75 nM ⌬rTcdA W101A, as shown by Western blot analysis (Fig. 4F, lower panel) . ⌬rTcdA W101A (1.5 nM) did not induce the up-regulation of RhoB. A densitometric analysis of three separate experiments is shown in Fig. 4E , lower panel.
In summary, this study evaluated tryptophan-101 mutant toxin A (rTcdA W101A) as a tool for studying glucosyltransferase-independent effects of C. difficile toxins because of its step-like concentration dependency on intact cells. rTcdA W101A has the same properties as wild-type rTcdA when applied at a 50-fold higher concentration than that of wild-type toxin to intact cells. At an equimolar concentration, the mutant toxin is inactive towards intact cells. In contrast to the enzyme activity-deficient DXD mutant, the remainder enzyme and cytopathic activity of the tryptophan mutant prove that it has correct toxic competence. The difference in GT activities in a cell-free system and in intact cells was shown to be due to intracellular conditions but not to uptake-mediated refolding of toxins.
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